Switzerland
# |
Name |
Free Cash Flow |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD -9.68 M
|
Dec. 31, 2023 | USD 2.03 | -1.93% |
|
Switzerland |
|
2 |
USD -43.06 M
|
Dec. 31, 2023 | USD 46.50 | 2.74% |
|
Switzerland |
|
3 |
USD -71.04 M
|
Dec. 31, 2023 | USD 5.48 | 3.60% |
|
Switzerland |
|
4 |
USD -121.90 M
|
Dec. 31, 2023 | USD 1.71 | -0.58% |
|
Switzerland |
The Clinical Trials company in Switzerland with the highest Free Cash Flow is NLS Pharmaceutics AG (NasdaqCM: NLSP) at USD -9.68 M.
The Clinical Trials company in Switzerland with the lowest Free Cash Flow is ADC Therapeutics SA (NYSE: ADCT) at USD -121.90 M.
The top 10 Clinical Trials companies in Switzerland by Free Cash Flow are NLS Pharmaceutics AG, MoonLake Immunotherapeutics, Molecular Partners AG and ADC Therapeutics SA.
The bottom 10 Clinical Trials companies in Switzerland by Free Cash Flow are ADC Therapeutics SA, Molecular Partners AG, MoonLake Immunotherapeutics and NLS Pharmaceutics AG.